Investment analysts at HC Wainwright boosted their FY2027 EPS estimates for shares of Oncolytics Biotech in a research report ...

Equities research analysts at Leede Financial boosted their FY2025 earnings per share (EPS) estimates for shares of ...

Oncolytics Biotech faces financial struggles and unclear pelareorep efficacy signals. Learn why ONCY stock's risks outweigh ...

Maxim lowered the firm’s price target on Oncolytics (ONCY) to $3 from $5 and keeps a Buy rating on the shares. The firm is adjusting its model ...

RBC Capital lowered the firm’s price target on Oncolytics (ONCY) to C$5 from C$6 and keeps an Outperform rating on the shares.Optimize Your ...

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today reported on highlights and financial results for Q4 and year ...

Oncolytics Biotech (ONCY) has disclosed a new risk, in the Corporate Activity and Growth category. Oncolytics Biotech faces significant business ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...